The best Rayyan alternatives in 2026 are Research Gold's screening tool (published accuracy benchmark, self-serve AI screening from $12 per month, PRISMA diagram included on the free tier), Covidence (Cochrane's standard platform, $339 per year as of mid 2026), EPPI-Reviewer (free for UK institutions), ASReview (free and open source), DistillerSR (enterprise), and Abstrackr (free, screening only). Researchers most often switch because Rayyan's flagship ResearchPilot AI is restricted to institutional plans, the free tier lacks a PRISMA flow diagram and automatic duplicate resolution, billing requires at least a quarterly commitment, and no accuracy numbers are published for any of its AI features. This guide compares all six alternatives on pricing, free tier contents, and AI access, then breaks down Rayyan's own pricing so you can decide whether switching is worth it at all.
Why Researchers Look for Rayyan Alternatives
Rayyan earned its enormous user base honestly: the free tier, the mobile app, and the widely cited Ouzzani et al. 2016 paper made it the default systematic review screening tool for a generation of graduate students. The reasons people leave are just as specific, and all of them come from Rayyan's own pages.
The advertised AI is not the AI you can buy. Rayyan's Advanced plan card promises that you can "accelerate screening with AI agents," yet Rayyan's own help center states that ResearchPilot, the suite containing the AI Reviewer and automatic extraction, is available exclusively on institutional plans. Those plans are custom quoted with a 5-license minimum. An individual researcher cannot purchase Rayyan's flagship AI screening at any price without a sales call, and the contradiction between the plan card and the help center makes it hard to know what a subscription actually includes.
The free tier withholds the two outputs beginners need most. The free plan includes neither the PRISMA flow diagram nor automatic duplicate resolution. You can detect duplicates, but resolving them in bulk requires a paid plan, and your journal-required flow diagram has to be built elsewhere. The much-praised mobile app allows only 100 screening decisions in total on the free tier, and you can invite just 2 free reviewers.
There is no monthly billing. As of mid 2026 the cheapest paid entry is $8.33 per month billed quarterly, roughly $25 up front, and the annual option requires a full year. Researchers who need a paid feature for a single screening month cannot buy one.
No published accuracy evidence. Rayyan claims its duplicate detection was "ranked #1 for accuracy and sensitivity in independent study," but the study is never cited or linked, and no recall, precision, or work-saved numbers are published for the relevance classifier or any ResearchPilot feature. For a methods section that has to defend screening accuracy, that is a real gap.
None of this makes Rayyan a bad tool. It means specific researchers, especially individuals who want verifiable AI-assisted screening and free PRISMA output, are better served elsewhere.